Bristol-Myers Squibb Company ($BMY) Stock Forecast: Down 5.1% Today

What is Bristol-Myers Squibb Company?

Bristol-Myers Squibb (NYSE: BMY) is a pharmaceutical company esteemed for its advancements in drug research and development within the healthcare industry. Today, the stock saw significant downward movement in the market.

Why is Bristol-Myers Squibb Company going down?

BMY stock is down 5.1% on May 14, 2025 18:40

• The stock price of Bristol-Myers Squibb declined notably following the company's agreement to pay $350 million to the State of Hawaiʻi for resolving claims tied to the prescription drug Plavix. Such substantial legal settlements have the potential to impact a company's financial standing and influence investor confidence, contributing to the bearish market activity.
• Today's 1.20% drop in BMY shares may also be a result of investors reassessing the stock's price-to-earnings ratio. Given the recent stock price decrease over the past month and a history of fluctuations, investors may be realigning their positions, further fueling the prevailing bearish sentiment.
• Despite witnessing a positive upturn of 4.70% in the past year, the recent legal settlement and broader market conditions could have overshadowed this growth, culminating in the observed bearish trajectory today.

BMY Price Chart

BMY Technical Analysis

BMY News

Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit - Bristol-Myers Squibb ( NYSE:BMY )

Bristol-Myers Squibb will pay $350 million to the State of Hawaiʻi to resolve all state claims related to the prescription drug Plavix. The state will dismiss its case and release all related claims; Sanofi US reached a similar but independent agreement for $350 million.

https://www.benzinga.com/general/biotech/25/05/45389547/bristol-myers-squibb-strikes-350-million-deal-to-end-hawaiis-plavix-lawsuit

A Look Into Bristol-Myers Squibb Inc's Price Over Earnings - Bristol-Myers Squibb ( NYSE:BMY )

Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.20% decrease. Over the past month, the stock decreased by 6.76%, but over the past year, it actually spiked by 4.70%.

https://www.benzinga.com/insights/news/25/05/45297571/a-look-into-bristol-myers-squibb-incs-price-over-earnings

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Up 6.8% Today

Toncoin ($TON) Crypto Forecast: Up 5.0% Today

Bristol-Myers Squibb Company Price History

04.03.2025 - BMY Stock was down 5.0%

• The bearish movement in BMY stock could be attributed to the overall market uncertainty and volatility caused by global trade tensions and tariff threats.
• Despite a positive opinion for label expansion of Opdivo, BMY's flagship drug, broader economic concerns and fears of a recession may have impacted market sentiment.
• Market fluctuations have been likened to Disney's Tower of Terror ride, illustrating the unpredictable nature of current market conditions.
• Investors may be approaching pharmaceutical stocks like BMY cautiously due to market turbulence, resulting in the bearish movement despite positive company developments.

07.02.2025 - BMY Stock was up 5.6%

• BMY outperformed the market with a strong bullish movement, closing higher than the previous day.
• The positive movement could be attributed to potential positive clinical trial results or regulatory approvals for one of its key drugs.
• Investors might be optimistic about BMY's future revenue prospects, leading to increased buying activity.
• The company's strong performance despite the overall market decline showcases investor confidence in BMY's resilience and growth potential.

31.09.2024 - BMY Stock was up 6.5%

• The anticipation of Bristol Myers' upcoming Q3 earnings report and the positive outlook on its new drugs have likely contributed to the bullish movement.
• Despite the overall market gains, the slight dip in BMY's stock price from the prior day's close could be attributed to profit-taking or minor market fluctuations.
• Investors seem optimistic about the company's future prospects, especially with the recent positive regulatory updates, which may have further boosted confidence in BMY's performance.

31.09.2024 - BMY Stock was up 5.0%

• Bristol-Myers Squibb (BMY) witnessed a strong bullish movement recently, fueled by its impressive third-quarter results and heightened annual earnings guidance.
• The company's performance was buoyed by surpassing earnings and sales projections, as well as robust demand for its blood thinner medication and new drugs, resulting in revenue growth.
• Positive regulatory developments and the robust adoption of new drugs have bolstered the stock's upward trajectory, positioning it as an appealing choice for investors.
• Despite a slight decline in the stock price in the latest trading session, the overall optimistic outlook and growth potential have propelled Bristol-Myers Squibb (BMY) ahead in the market.

26.06.2024 - BMY Stock was up 10.3%

• Bristol Myers Squibb (BMY) delivered impressive Q2 results, surpassing expectations for both earnings per share and revenue, underscoring robust financial performance.
• The optimistic earnings call transcript and the company's ability to outstrip analyst projections likely boosted investor confidence, contributing to the upward movement.
• The general positive market sentiment, with U.S. stocks exhibiting gains and major indices like the Dow, NASDAQ, and S&P 500 showing positive trends, provided a supportive environment for BMY's upward trajectory.
• Amidst dynamic stock movements, the company's strong performance in the pharmaceutical sector solidified its position as a leading performer, attracting investor attention and propelling the stock price upwards.

26.06.2024 - BMY Stock was up 8.1%

• Bristol-Myers Squibb reported higher revenues and net profit for the second quarter of 2024, surpassing estimates and showing a significant increase year-over-year.
• The stock's positive performance can be attributed to the company's strong second-quarter results, particularly driven by the Growth Portfolio and the success of Eliquis.
• Additionally, Bristol-Myers Squibb's late-stage trial win further boosted investor confidence and contributed to the bullish movement in the stock.
• The overall market sentiment, with US equity futures rebounding and tech names showing gains, also provided a favorable environment for Bristol-Myers Squibb's stock to thrive amidst positive macroeconomic factors.

26.06.2024 - BMY Stock was up 8.3%

• Bristol-Myers Squibb (BMY) exceeded both earnings per share (EPS) and revenue expectations for the second quarter of 2024, showcasing strong financial performance.
• The company's positive Q2 results, including higher revenue and profit, along with an increase in full-year guidance, contributed to the bullish movement in the stock.
• Market sentiment was further boosted by the company's ability to outperform analyst estimates, leading to increased investor confidence and driving the stock price higher.
• Overall, Bristol-Myers Squibb's solid financial performance and optimistic outlook on rising drug sales propelled the stock to a bullish trajectory, attracting investors seeking growth opportunities in the biopharmaceutical sector.

26.06.2024 - BMY Stock was up 8.6%

• Bristol Myers Squibb posted second-quarter revenues that surpassed expectations, driven by the Growth Portfolio and Eliquis, leading to increased investor confidence and a bullish movement in the stock.
• The company raised its 2024 non-GAAP guidance, indicating a positive outlook for future earnings and revenue, which likely contributed to the bullish sentiment among investors.
• Despite a decrease in Q2 profit compared to last year, Bristol Myers Squibb managed to beat Street estimates, showcasing resilience and efficiency in its operations, further boosting investor optimism.
• The overall rebound in US equity futures and positive performance of mega-cap tech companies like NVDA, AMZN, and AAPL might have also contributed to the bullish market movement, creating a favorable trading environment for stocks like BMY.

24.06.2024 - BMY Stock was up 5.0%

• Despite concerns about potential challenges ahead of the second-quarter results, investors appear to have shown confidence in BMY today.
• The bullish movement could be linked to the European Medicines Agency (EMA) commencing the review process for Bristol Myers' application for Opdivo Plus Yervoy for advanced hepatocellular carcinoma, signaling potential positive developments in the company's drug approval process.
• Additionally, the overall positive sentiment towards pharmaceutical companies, with major players pursuing deals in China to fortify their drug pipelines, might have influenced the bullish movement in BMY.
• The focus on defensive stocks due to economic uncertainties and policy concerns could have also driven investors to seek stability in pharmaceutical companies like Bristol Myers, recognized for their resilience during challenging economic conditions.

30.06.2024 - BMY Stock was down 5.5%

• Analyst Carter Gould revised BMY's rating to Underweight while upholding the price target at $41, potentially impacting the downtrend.
• The mixed analyst sentiment and recent stock movements discussed by a financial expert may have intensified the selling pressure on BMY shares.
• The prevailing bearish sentiment surrounding BMY stands in contrast to the upbeat earnings season, hinting at specific company-specific factors causing the downturn.
• The adverse forecasts from prominent Wall Street analysts and the broader market movement affecting stocks like BMY, Abbive, and Tesla likely contributed to the downward pressure on Bristol-Myers Squibb's stock.

10.03.2025 - BMY Stock was down 6.1%

• The FDA approval for the label expansion of Opdivo plus Yervoy combo for colorectal cancer reflects positively on BMY, showcasing the company's dedication to addressing unmet medical needs.
• Despite this favorable development, the stock faced a bearish trend today, possibly due to investors taking profits, considering the approval had already been factored into the stock price.
• Investor apprehensions regarding the competitive environment in oncology or overall market conditions may have led to the sell-off of BMY shares, despite the encouraging regulatory update.
• Investors are advised to evaluate the long-term implications of BMY's extended label approval and its potential impact on the company's revenue and market standing in the oncology sector.

14.04.2025 - BMY Stock was down 5.1%

• The stock price of Bristol-Myers Squibb declined notably following the company's agreement to pay $350 million to the State of Hawaiʻi for resolving claims tied to the prescription drug Plavix. Such substantial legal settlements have the potential to impact a company's financial standing and influence investor confidence, contributing to the bearish market activity.
• Today's 1.20% drop in BMY shares may also be a result of investors reassessing the stock's price-to-earnings ratio. Given the recent stock price decrease over the past month and a history of fluctuations, investors may be realigning their positions, further fueling the prevailing bearish sentiment.
• Despite witnessing a positive upturn of 4.70% in the past year, the recent legal settlement and broader market conditions could have overshadowed this growth, culminating in the observed bearish trajectory today.